Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
AEON Biopharma, Inc. (AEON) is the subject of a Schedule 13G reporting 7,362,438 shares of Class A common stock, or 9.9%, as beneficially owned by each reporting person, Ikarian Capital, LLC and Neil Shahrestani. The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts. Ikarian Capital manages the fund and accounts, and Shahrestani may be deemed to own the securities indirectly through his control of Ikarian Capital.
The reported amount includes 2,181,063 shares acquirable within 60 days under warrants. Conversion is restricted if it would cause the reporting persons’ beneficial ownership to exceed 9.99% of outstanding shares. The percentage calculation uses 73,698,083 shares, including warrant shares, and cites 71,517,020 shares outstanding as of October 30, 2026.
Key Figures
Beneficial ownership:7,362,438 sharesPercentage of class:9.9%Warrant shares:2,181,063 shares+3 more
6 metrics
Beneficial ownership7,362,438 sharesReported by each reporting person; includes shares acquirable under warrants.
Percentage of class9.9%Reported beneficial ownership percentage.
Warrant shares2,181,063 sharesMay be acquired within 60 days; conversion is subject to a 9.99% restriction.
Conversion restriction threshold9.99%Restriction applies if conversion would cause beneficial ownership to exceed this percentage of outstanding shares.
Shares outstanding71,517,020 sharesAs of October 30, 2026, as cited in the ownership percentage calculation.
Percentage calculation base73,698,083 sharesIncludes the warrant shares and the 71,517,020 shares outstanding as of October 30, 2026.
Key Terms
beneficial ownership, separately managed accounts, warrants, investment discretion, +2 more
6 terms
beneficial ownershipregulatory
"Amount beneficially owned"
Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.
separately managed accountsfinancial
"the Fund and certain separately managed accounts"
A separately managed account is an investment portfolio owned by a single investor but professionally managed to that investor’s specific goals and preferences, rather than pooled with other clients’ money. It matters to investors because it offers greater customization, tax control and transparency—like hiring a personal chef instead of eating from a shared buffet—though it often requires higher minimums and can have different fee and liquidity implications.
warrantsfinancial
"shares ... may be acquired ... pursuant to warrants"
Warrants are special documents that give you the right to buy a company's stock at a set price before a certain date. They are often used as a way for companies to attract investors or raise money, and their value can increase if the company's stock price goes up.
investment discretionfinancial
"through the investment discretion it has over the Fund"
shared voting powerregulatory
"Shared Voting Power 7,362,438.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive powerregulatory
"Shared Dispositive Power 7,362,438.00"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How many AEON shares did Ikarian Capital and Neil Shahrestani report owning?
Each reported beneficial ownership of 7,362,438 shares, or 9.9% of AEON’s Class A common stock. The securities are held by Ikarian Healthcare Master Fund, L.P. and certain separately managed accounts.
How do warrants affect Ikarian Capital’s reported AEON ownership?
The reported amount includes 2,181,063 shares acquirable within 60 days under warrants. Conversion is restricted if it would cause the reporting persons’ beneficial ownership to exceed 9.99% of outstanding shares. The percentage calculation uses 73,698,083 shares, including warrant shares, and cites 71,517,020 shares outstanding as of October 30, 2026.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
UNDER THE SECURITIES EXCHANGE ACT OF 1934
AEON Biopharma, Inc.
(Name of Issuer)
Class A common stock, $0.0001 par value per share
(Title of Class of Securities)
00791X209
(CUSIP Number)
09/30/2026
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)
schemaVersion:
SCHEDULE 13G
CUSIP Number(s):
00791X209
1
Names of Reporting Persons
Ikarian Capital, LLC
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
DELAWARE
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,362,438.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,362,438.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,362,438.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
IA
Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Class A common stock, $0.0001 par value per share ("Common Stock") of AEON Biopharma, Inc. (the "Issuer") held by Ikarian Healthcare Master Fund, L.P., a Cayman Islands exempted limited partnership (the "Fund"), and certain separately managed accounts. See Item 2 for more information.
(2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer.
(3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on November 2, 2026.
SCHEDULE 13G
CUSIP Number(s):
00791X209
1
Names of Reporting Persons
Neil Shahrestani
2
Check the appropriate box if a member of a Group (see instructions)
(a)
(b)
3
Sec Use Only
4
Citizenship or Place of Organization
UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:
5
Sole Voting Power
0.00
6
Shared Voting Power
7,362,438.00
7
Sole Dispositive Power
0.00
8
Shared Dispositive Power
7,362,438.00
9
Aggregate Amount Beneficially Owned by Each Reporting Person
7,362,438.00
10
Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
11
Percent of class represented by amount in row (9)
9.9 %
12
Type of Reporting Person (See Instructions)
HC, IN
Comment for Type of Reporting Person: (1) The figures in Items 6, 8, 9, and 11 represent Common Stock of the Issuer held by the Fund and certain separately managed accounts. See Item 2 for more information.
(2) The figures in Items 6, 8, 9, and 11 include 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons within 60 days pursuant to warrants held by the Reporting Persons, the exercise of which are subject to certain restrictions on the ability of the Reporting Persons to convert such warrants if, upon such conversion, the number of shares of Common Stock of the Issuer then beneficially owned by the Reporting Persons would exceed 9.99% of the outstanding shares of Common Stock of the Issuer.
(3) The figure in Item 11 is based upon 73,698,083 shares of Common Stock of the Issuer outstanding, which includes the 2,181,063 shares of Common Stock of the Issuer that may be acquired by the Reporting Persons pursuant to warrants and the 71,517,020 shares of Common Stock of the Issuer outstanding as of October 30, 2026, as disclosed in the Issuer's Form 8-K filed with the SEC on November 2, 2026.
SCHEDULE 13G
Item 1.
(a)
Name of issuer:
AEON Biopharma, Inc.
(b)
Address of issuer's principal executive offices:
130 Vantis Drive, Suite 170, Aliso Viejo, CA 92656
Item 2.
(a)
Name of person filing:
This statement is filed jointly by and on behalf of each of Ikarian Capital, LLC, a Delaware limited liability company ("Ikarian Capital"), and Neil Shahrestani (together referred herein as the "Reporting Persons"). The Fund, and certain separately managed accounts managed by Ikarian Capital (collectively, the "Managed Accounts"), are the record owners of the securities covered by this statement. Ikarian Capital is an investment adviser registered under the Investment Advisers Act of 1940, as amended, and serves as investment manager to the Fund and as sub-adviser to the Managed Accounts, and may be deemed to have beneficial ownership of the securities covered by this statement through the investment discretion it has over the Fund and the Managed Accounts. Ikarian Capital is ultimately controlled, indirectly, by Mr. Shahrestani. Accordingly, Mr. Shahrestani may be deemed to indirectly beneficially own securities beneficially owned by Ikarian Capital. The Fund disclaims beneficial ownership of the shares held by the Managed Accounts. The Managed Accounts disclaim beneficial ownership of the shares held by the Fund.
Each Reporting Person declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purposes of Section 13(d) or 13(g) of the Act or any other purpose, the beneficial owner of any securities covered by this statement.
Each Reporting Person may be deemed to be a member of a group with respect to the issuer or securities of the issuer for the purpose of Section 13(d) or 13(g) of the Act. Each of the Reporting Persons declares that neither the filing of this statement nor anything herein shall be construed as an admission that such person is, for the purpose of Section 13(d) or 13(g) of the Act or any other purpose, (i) acting (or has agreed or is agreeing to act together with any other person) as a partnership, limited partnership, syndicate, or other group for the purpose of acquiring, holding, or disposing of securities of the issuer or otherwise with respect to the issuer or any securities of the issuer or (ii) a member of any group with respect to the issuer or any securities of the issuer.
(b)
Address or principal business office or, if none, residence:
The address of the principal business office of each of the Reporting Persons is c/o Ikarian Capital, LLC, 100 Crescent Court, Suite 1620, Dallas, Texas 75201.
(c)
Citizenship:
See Item 4 on the cover page hereto
(d)
Title of class of securities:
Class A common stock, $0.0001 par value per share
(e)
CUSIP Number(s):
00791X209
Item 3.
If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)
Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)
Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)
Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)
Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)
An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)
An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)
A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)
A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)
A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)
A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:
(k)
Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.
Ownership
(a)
Amount beneficially owned:
See Item 9 on the cover page(s) hereto.
(b)
Percent of class:
See Item 11 on the cover page(s) hereto.
(c)
Number of shares as to which the person has:
(i) Sole power to vote or to direct the vote:
See Item 5 on the cover page(s) hereto.
(ii) Shared power to vote or to direct the vote:
See Item 6 on the cover page(s) hereto.
(iii) Sole power to dispose or to direct the disposition of:
See Item 7 on the cover page(s) hereto.
(iv) Shared power to dispose or to direct the disposition of:
See Item 8 on the cover page(s) hereto.
Item 5.
Ownership of 5 Percent or Less of a Class.
Not Applicable
Item 6.
Ownership of more than 5 Percent on Behalf of Another Person.
If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
The information set forth in Item 2(a) is incorporated by reference herein.
Item 7.
Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
Not Applicable
Item 8.
Identification and Classification of Members of the Group.
Not Applicable
Item 9.
Notice of Dissolution of Group.
Not Applicable
Item 10.
Certifications:
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.